Navigation Links
News of plaque-clearing drug tops week of major advances against Alzheimer's disease
Date:2/10/2012

Clarksburg, MD"In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease," said Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation (AHAF), a nonprofit that identifies and funds exceptionally high-impact research worldwide through its Alzheimer's Disease Research program.

"We are excited about today's announcement by Case Western University researchers that a cancer drug, used in mice studies, appears to help clear out the excess plaque found in the Alzheimer's-disease brain and it does this by enhancing the body's natural defense mechanisms," noted Haller. "This follows last week's announced discovery of how Alzheimer's disease spreads in the brain. The timing of these findings coincides with new proposals in Congress and the White House to increase federal funding for Alzheimer's research. This has been a big week for all who seek to end this disease."

In a study of mice, a research team headed by Case Western University scientist Gary Landreth, Ph.D., found that bexarotenea drug currently used to combat T cell lymphoma helped the body clear out amyloid beta proteins. Alzheimer's disease arises in large part from the body's inability to clear these naturally occurring proteins. As amyloid beta levels increase they tend to aggregate and contribute to the so-called brain "plaques" found in Alzheimer's disease.

Bexarotene appeared to improve brain function in these mice. Study results were published in the journal Science.

"Although this is a mouse study, the results are encouraging, and the drug did its job with unprecedented speed, by targeting ApoE, the primary genetic risk factor for Alzheimer's disease," said AHAF Vice President for Scientific Affairs Guy Eakin, Ph.D.

"This announcement is particularly exciting because bexarotene achieved regulatory approval by the U.S. Food and Drug Administration more than a decade ago for the treatment of cancer. That earlier approval could speed up the prospects for human clinical trials of the drug as an Alzheimer's treatment."

AHAF, which had also supported Landreth earlier in his career, started funding the preliminary work leading to this line of research in 2007. Currently, AHAF is funding follow-up studies in which the Landreth team is testing the latest findings on other "mouse models" that may better represent the human form of Alzheimer's disease. Positive findings could help pave the way towards human clinical studies.

"While it is still too early to make predictions, if these findings can be replicated in additional preclinical studies, and then later in human clinical trials, we may have a powerful new weapon in the battle to halt this disease," noted Eakin.

This latest news comes only one week after an AHAF-funded research team in Boston and another team in New York announced a major breakthrough in understanding how Alzheimer's disease spreads in the brain. By learning that toxic "tau" proteins jump from nerve cell to nerve cell, scientists can now focus on ways to target and stop this cell-to-cell spread.

Although these reports are coming in rapid succession, the overall progress of Alzheimer's disease research has been slower than that of other major diseases, due in part to comparatively meager financial support for Alzheimer's disease research. "We hope this funding scenario will improve, as promising study results stimulate our national resolve to defeat this disease," said Haller.

This week the Obama Administration announced it will provide an additional $130 million in Alzheimer's research funding over the next two years. Last week a bipartisan group in Congress unveiled the Spending Reductions through Innovations in Therapies (SPRINT) Agenda Act of 2012. The legislation, introduced by Senators Barbara Mikulski (D-MD) and Susan Collins (R-ME) and Representatives Chris Smith (R-NJ) and Ed Markey (D-MA), would spur public and private research funding and streamline the regulatory review of treatments.


'/>"/>

Contact: Alice L. Kirkman
akirkman@ahaf.org
301-556-9349
AHAF-American Health Assistance Foundation
Source:Eurekalert

Related biology news :

1. Monogamy reduces major social problems of polygamist cultures
2. University of Texas chemist receives major grant to improve detection of drug-resistant tuberculosis
3. New EPA air quality rules outweigh costs and provide major health and environmental benefits
4. A major step forward towards drought tolerance in crops
5. National Science Foundation awards major grant to Cary Institute
6. Salads you can trust -- safe farm practices get major test
7. Southampton professor awarded major funding for Biophotonics programme
8. FSU professor wins major meteorology award for research on El Nino
9. CO2 bonds in sea ice: Small living creatures with major impact
10. University of Houston physicist part of major solar energy research team
11. On the trail of biomarkers and signalling substances with major instrumentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
Breaking Biology Technology: